Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
834K
-
Shares change
-
-91M
-
Total reported value, excl. options
-
$2.72M
-
Value change
-
-$68.4M
-
Number of sells
-
-43
-
Price
-
$3.20
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2023
44 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q3 2023.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 834K shares
of 28.5M outstanding shares and own 2.93% of the company stock.
Largest 10 shareholders include AWM Investment Company, Inc. (719K shares), Defender Capital, LLC. (115K shares), Avior Wealth Management, LLC (0 shares), LEE DANNER & BASS INC (0 shares), Bank of New York Mellon Corp (0 shares), Raymond James Financial Services Advisors, Inc. (0 shares), Lindbrook Capital, LLC (0 shares), WEALTH EFFECTS LLC (0 shares), ALBION FINANCIAL GROUP /UT (0 shares), and PURA VIDA INVESTMENTS, LLC (0 shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.